Koen Andries
Koen Andries is a Belgian Janssen Pharmaceutica and professor at the University of Antwerp. In 2005 he and his team published a discovery about a new di-Aryl-Quinoline-based drug (R207910) which promises a shorter and simpler treatment for Tuberculosis (TB).[1]
Career
He graduated as a Veterinarian and obtained a PhD at the University of Ghent (Ghent, Belgium) in 1975. He continued his career at the university until 1982, when he started working at Janssen Pharmaceutica in Beerse until 2004. In 2004 he continued his research at Tibotec in Mechelen.
Recognition
- 2014 winner of the European Inventor Award in the Industry category [2] awarded by the European Patent Office
References
- ↑ Andries K, Verhasselt P, Guillemont J, et al. (2005), A diarylquinoline drug active on the ATP-synthase of Mycobacterium tuberculosis, Science 307 (5707): 223–27
- ↑ Invention: Drug against multidrug-resistant tuberculosis
Source
- Cohen, MEDICINE: New TB Drug Promises Shorter, Simpler Treatment, Science 10 December 2004: 1872
- World: New Drugs Show Promise In Fight Against Tuberculosis
- New tuberculosis antibiotic may shorten treatment time, fight drug-resistant strains
External links
- Koen Andries (University of Antwerp)
- Koen Andries and his team (European Patent Office)
This article is issued from Wikipedia - version of the Wednesday, October 08, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.